Towards the genetic basis of cerebral venous thrombosis-the BEAST Consortium

Cotlarciuc, Ioana

2016


http://hdl.handle.net/10138/174951
https://doi.org/10.1136/bmjopen-2016-012351

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.
Towards the genetic basis of cerebral venous thrombosis—the BEAST Consortium: a study protocol

Ioana Cotlarciuc,1 Thomas Marjot,2 Muhammad S Khan,3 Sini Hiltunen,4 Elena Haapaniemi,4 Tiina M Metso,4 Jukka Putaala,4 Susanna M Zuurbier,5 Matthijs C Brouwer,5 Serena M Passamonti,6 Paolo Bucciarelli,6 Emanuela Pappalardo,6 Tasmin Patel,1 Paolo Costa,7 Marina Colombi,8 Patrícia Canhão,9 Aleksander Tkach,10 Rosa Santacroce,11 Maurizio Margaglione,11 Giovanni Favuzzi,12 Elvira Grandone,12 Donatella Colaizzo,12 Kostas Spengos,13 Antonio Arauz,14 Amanda Hodge,15 Reina Ditta,15 Stephanie Debette,16 Marialuiza Zedde,17 Guillaume Pare,15 José M Ferro,9 Vincent Thijs,18 Alessandro Pezzini,7 Jennifer J Majersik,10 Ida Martinelli,6 Jonathan M Coutinho,5 Turgut Tatlisumak,4,19,20 Pankaj Sharma,1
on behalf of the ISGC (International Stroke Genetics Consortium) and BEAST investigators

To cite: Cotlarciuc I, Marjot T, Khan MS, et al. BMJ Open 2016;6:e012351. doi:10.1136/bmjopen-2016-012351

IC and TM contributed equally to this work

To view these files please visit the journal online (http://dx.doi.org/10.1136/bmjopen-2016-012351).

ABSTRACT

Introduction: Cerebral venous thrombosis (CVT) is a rare cerebrovascular condition accounting for <1% of all stroke cases and mainly affects young adults. Its genetic aetiology is not clearly elucidated.

Methods and analysis: To better understand the genetic basis of CVT, we have established an international biobank of CVT cases, Biorepository to Establish the Aetiology of Sinovenous Thrombosis (BEAST) which aims to recruit highly phenotyped cases initially of European descent and later from other populations. To date we have recruited 745 CVT cases from 12 research centres. As an initial step, the consortium plans to undertake a genome-wide association analysis of CVT using the Illumina Infinium HumanCoreExome BeadChip to assess the association and impact of common and low-frequency genetic variants on CVT risk by using a case–control study design. Replication will be performed to confirm putative findings. Furthermore, we aim to identify interactions of genetic variants with several environmental and comorbidity factors which will likely contribute to improve the understanding of the biological mechanisms underlying this complex disease.

Ethics and dissemination: BEAST meets all ethical standards set by local institutional review boards for each of the participating sites. The research outcomes will be published in international peer-reviewed open-access journals with high impact and visibility. The results will be presented at national and international meetings to highlight the contributions into improving the understanding of the mechanisms underlying this uncommon but important disease. This international DNA repository will become an important resource for investigators in the field of haematological and vascular disorders.

Strengths and limitations of this study

▪ This study is the largest collaboration on cerebral venous thrombosis (CVT) conducted to-date and has the advantage that it includes highly phenotyped individuals.
▪ This is the first study that aims to perform a genome-wide association analysis to assess the association and impact of common and low-frequency genetic variants on CVT risk.
▪ Identifying genetic variants associated with CVT risk will likely contribute to improving our understanding of the biological mechanisms underlying this disease and may lead to the discovery of novel therapeutic targets.
▪ A potential limitation of the study is the difficulty of recruiting a large number of cases due to the very low incidence and prevalence of this condition. Major efforts are being made to include as many research centres able to investigate this disease across Europe and beyond.

BACKGROUND

Cerebral venous thrombosis (CVT) is a rare cerebrovascular condition that accounts for <1% of all strokes,1 with an overall annual incidence estimated at 1.32 per 100 000 person-years.2 CVT commonly affects young...
adults and is more prevalent in women, accounting for ~75% of the adult affected patients. It can lead to mortality or severe morbidity but generally has a good clinical outcome particularly following early identification of less severe cases using advanced imaging.

The condition has two broadly different aetiological mechanisms: thrombosis of cerebral veins with local effects caused by venous obstruction and thrombosis of the dural sinuses which may cause intracranial hypertension.

However, both processes usually occur simultaneously in most patients with thrombosis often present in more than one sinus. Compared with arterial thrombosis, CVT is less frequent in terms of incidence and more variable in its clinical presentation and neuroimaging.

The condition has multiple risk factors (Box 1) and presents as a diagnostic and therapeutic challenge given the diversity of symptomatic presentation and variety of putative aetiological factors.

CVT is a rare manifestation of venous thromboembolism (VTE). Compared with CVT, traditional venous thrombosis manifestations such as deep vein thrombosis (DVT) and pulmonary embolism (PE) are much more common and are diseases of ageing.

There is a lack of data evaluating the risk of CVT recurrence, as well as whether the risk factors for CVT are similar to those for DVT and PE. One recent study has found that after a 10-year follow-up on patients with DVT and PE only 5.2% developed CVT, while for patients with CVT only 5.8% developed DVT/PE later on. Therefore, no significant link between CVT and DVT/PE has been found so far.

Interestingly, one study has found no differences in thrombophilia markers between CVT and patients with DVT/PE; however, the frequency of other risk factors, such as oral contraceptive (OC) use, pregnancy or puerperium was significantly different. CVT showed to be more frequent in women, secondary to hormonal factors and less often secondary to trauma, immobilisation or surgery compared with patients with DVT/PE.

Therefore, it is not clear why CVT occurs less often than DVT/PE, and age-dependent differences in the risk profile between CVT and DVT/PE, as well as genetic factors may play a role in the pathogenesis. Thus, due to its rarity and risk profile, CVT represents a particular form of VTE.

Neither the genetic component of CVT nor its heritability has been widely assessed mainly because of its low incidence and lack of large number of cases. However, there is reasonable evidence to support a genetic predisposition to CVT.

A significant proportion of cases (~13–25%) have no risk factors identified suggesting that undetermined genetic factors may at least partly account for this unexplained risk. Although it is a more rare condition, it does not usually cluster in families and there is no evidence to suggest a Mendelian inheritance.

The genetic component of CVT has so far been assessed mainly by candidate gene studies. As CVT is

**Box 1 Risk factors associated with cerebral venous thrombosis**

- Genetic prothrombotic conditions
  - Antithrombin deficiency
  - Protein C and S deficiency
  - Factor V Leiden mutation
  - Prothrombin G20120A mutation
  - Hyperhomocysteinaemia caused by MTHFR C677T polymorphism
- Acquired prothrombotic states
  - Nephrotic syndrome
  - Antiphospholipid antibodies
  - Pregnancy
  - Puerperium
- Systemic inflammatory disease
  - Systemic lupus erythematosus
  - Inflammatory bowel disease
  - Wegener’s granulomatosis
  - Behcet’s syndrome
  - Sarcoidosis
  - Thyroid disease
- Systemic infectious disease
  - Bacterial: septicaemia, endocarditis, typhoid, tuberculosis
  - Viral: measles, hepatitis, encephalitis, herpes, HIV, cytomegalovirus
  - Parasitic: malaria, trichinosis
  - Fungal: aspergillosis
- Head and neck infections
  - Extradural: mastoiditis, sinuses, otitis, facial cellulitis, osteomyelitis, tonsillitis
  - Intradural/parenchymal: abscess, empyema, meningitis
- Haematological disorders
  - Polycythaemia (primary and secondary)
  - Thrombocytopenia
  - Anaemia (including paroxysmal nocturnal haemoglobinuria)
  - Sickle cell disease
- Drugs
  - Oral contraceptives
  - L-asparaginase therapy
  - Hormone supplement therapy
- Systemic malignancies
  - Visceral carcinomas
  - Lymphomas
  - Leukaemia
  - Myeloproliferative disease
- Central nervous system tumours
  - Meningioma, metastases, carcinomatous infiltration
- Gastrointestinal disease
  - Ulcerative colitis, Crohn’s disease
- Cardiac disease
  - Congenital heart disease, cardiac insufficiency
- Mechanical causes and trauma
  - Head injury, injury to sinuses or jugular vein, neurosurgical procedures, jugular vein catheterisation, lumbar puncture
- Others
  - Cerebral infarcts and haemorrhage
  - Arteriovenous malformations
  - Dural arteriovenous malformation
  - Arachnoid cyst
  - Internal jugular compression
  - Severe exfoliative dermatitis
  - Severe dehydration of any cause
- Idiopathic
known to be associated with inherited thrombophilia, most candidate gene studies have assessed mutations associated with this condition such as factor V Leiden and prothrombin G20120A mutation. Other mutations investigated by candidate gene studies have included the MTHFR C677T polymorphism (risk factor for hyperhomocysteinaemia), the plasminogen activator inhibitor-1 4G/5G polymorphism (risk factor for thrombosis), protein Z G79A polymorphism (involved in formation of blood clots) and Janus Kinase-2 V617F mutation (involved in making haematopoietic cells more sensitive to growth factors). However, the results from such individual candidate gene studies have been conflicting mainly because of lack of sufficient power due to the low number of cases. One large meta-analysis on 1183 CVT cases and 5189 controls that pooled together results from 26 candidate gene studies highlighted significant associations of factor V Leiden G1691A mutation (OR=2.40; 95% CI 1.75 to 3.30; p<10⁻⁵) and prothrombin G20120A mutation (OR=5.48; 95% CI 3.88 to 7.74; p<10⁻⁵) in adult populations. Interestingly, this study also found that genes involved in the clotting cascade provide a greater level of thrombosis risk in the cerebral venous circulation compared with its arterial circulation implying a larger genetic liability for CVT compared with sporadic ischaemic stroke (IS). Moreover, previous studies suggested a stronger genetic component in younger patients who had stroke compared with older case of stroke providing additional evidence to support a strong genetic susceptibility to CVT.

Other thrombophilic factors involved in the coagulation pathway that are associated with an increased risk of CVT are: protein C, protein S and antithrombin deficiencies. These prothrombotic factors are also associated with an increased risk of DVT and PE suggesting that all these venous thrombosis conditions may have a common genetic component.

An important characteristic of the disease is the higher prevalence in women. Large epidemiological studies have confirmed that OC users, particularly users of third-generation OCs, are at increased risk of VTE. Although contraceptive drugs are an important factor in explaining this gender distribution, genetic factors interacting with pharmacological or environmental determinants may also play a significant role. In addition, very little is known about why the rate of CVT is relatively low given widespread environmental exposures on a population level (eg, OCs, sinus infections, etc), suggesting that an underlying background genetic risk may contribute to increasing the incidence of CVT in those with common exposures.

To better understand the genetic basis of CVT, we have established an international biorepository of highly characterised CVT cases. Biorepository to Establish the Aetiology of Sinovenous Thrombosis (BEAST). The BEAST Consortium includes CVT cases recruited currently from 10 centres across seven countries in Europe, and one each from the USA and Mexico.

Our study aims first to assess the association and impact of common and low-frequency genetic variants on CVT risk by using a case–control study design and second, to identify interactions of genetic variants with several environmental and comorbidity factors which collectively will likely contribute to a better understanding of the biological mechanisms underlying this complex disease.

**METHODS**

**Study participants**

**Cases**

The ongoing international BEAST Consortium has to-date recruited DNA and clinical data from 745 patients with CVT (aged ≥18 years) from 12 research centres located in the following countries: Belgium, Finland, Greece, Italy, the Netherlands, Portugal, UK, USA and Mexico.

In all cases, CVT is confirmed by CT or MRI of the brain and dedicated venography (CT angiography, MR angiography, or conventional angiogram). The inclusion criteria for cases are presented in table 1. Detailed phenotypic data is provided by each participating centre (box 2).

Owing to differences in the genetic structure between the different populations participating in the study, cases will be split for genetic association analysis into four groups: West European, South European (Italian and Portuguese), Finnish and Mexican cases, to obtain homogeneous populations. The US population is all European origin (non-Hispanic white). The results will be presented per ancestral population and then subjected to a pooled meta-analysis of all populations.

**Controls**

The inclusion criteria for the control population are presented in table 1.

For the West European CVT cohort, the BEAST study will use data from previously genotyped control samples, namely 2469 British controls from the 1958 British Birth Cohort part of the Wellcome Trust Case Control Consortium (WTCCC). In addition, we have recruited healthy age-matched and sex-matched controls numbering 300 Italians for

**Table 1** Inclusion criteria for CVT cases and controls

<table>
<thead>
<tr>
<th>Inclusion criteria for CVT cases</th>
<th>Inclusion criteria for controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥18 years at the time of enrolment</td>
<td>Age ≥18 years at the time of enrolment</td>
</tr>
<tr>
<td>CVT determined using: ▶ CT or MRI brain ▶ Dedicated venography (CTA, MRA, or conventional angiogram)</td>
<td>No history of CVT/ stroke or any other thrombotic or chronic condition</td>
</tr>
<tr>
<td>Patient or relative provision of informed written consent</td>
<td>Provision of informed written consent</td>
</tr>
</tbody>
</table>

CTA, CT angiography; CVT, cerebral venous thrombosis; MRA, MR angiography.
the South European cohort, 230 Finnish for the Finnish cohort and 100 Mexicans for the Mexican cohort.

**Ethical considerations**

BEAST meets all ethical standards set by local institutional review boards for each of the participating sites. Written informed consent is obtained for all patients with CVT and controls at each participating research centre. Patient confidentiality is protected and patient details are encrypted.

**Biological samples**

Peripheral blood samples from all participants are collected in EDTA-coated phials or sodium citrate vacutainers using venipuncture. Genomic DNA is extracted from peripheral blood using commercially available DNA isolation kits and stored at −80°C.

**Genotyping**

**Cases**

DNA samples for all CVT cases will be processed on the HumanCoreExome BeadChip v1.0 (Illumina, San Diego, California, USA) using standard protocols at the Genetic and Molecular Epidemiology Laboratory, McMaster University, Canada.

The Illumina Infinium HumanCoreExome BeadChip contains ~240 000 exome focused markers, as well as ~240 000 common tagSNP markers. The functional exonic markers include non-synonymous variants, stop altering variants, splice coding variants and variants located in promoter regions.

**Controls**

The WTCCC British control sample was genotyped using the HumanExome BeadChip v1.0 (Illumina, San Diego, California, USA). The Illumina HumanExome Beadchip includes 247 870 markers focused on protein-altering variants selected from >12 000 exome and genome sequences representing multiple ethnicities and complex traits.

The Finnish controls have already been genotyped using the Illumina Infinium HumanCoreExome BeadChip, while other control samples (Italian and Mexican) will be genotyped with the same array.

**Data analysis**

We will perform case–control analysis using logistic regression assuming an additive genetic model to assess the association of the genotyped markers with CVT risk. Rigorous quality control procedures will be applied according to the recommended exome chip processing protocol.30

Population stratification analysis and testing for relatedness will be conducted, and outliers will be removed from analysis. To investigate residual population stratification, genomic inflation factors will be calculated. Quantile-Quantile plots will be constructed to assess the quality of the association results. Meta-analysis of the association results for the participating cohorts will be performed using a fixed effect model and inverse variance method of weighted β coefficients and SEs from each study. Furthermore, the putative positive findings will be confirmed by replication in independent samples to exclude spurious associations. We are currently collaborating with additional centres to recruit a replication sample.

We will conduct a reciprocal look up in genome-wide association studies (GWAS) of other venous thrombosis conditions (DVT/PE) and potentially pooling of analyses from these studies if available.

We will undertake a subgroup analysis of CVT cases with and without history of other venous thrombosis conditions (DVT/PE). We will also undertake a subgroup analysis of CVT cases with and without inherited thrombophilia.

We will assess the interactions of significant polymorphisms with environmental and comorbidity risk factors, severity of clinical presentation and outcome.

The power for gene-environment interactions depends on the magnitude of the environmental exposure frequency. Therefore, the power is higher if the exposure frequency is low and is lower if the exposure is high.31

---

**Box 2 Phenotypic data provided by each participating centre**

- Demographic data (age, sex, ethnicity).
- Date of cerebral venous thrombosis diagnosis.
- Clinical presentation and symptoms.
- Neuroimaging information including sinus/vein involved and extent of oedema, haemorrhage.
- Family history of thrombotic or cerebrovascular event.
- Thrombophilia screening information:
  - Protein C and S deficiencies,
  - Genetic polymorphisms (factor V G1691A mutation, prothrombin G20210A mutation),
  - Antiphospholipid antibodies,
  - Lupus anticoagulant,
  - Hyperhomocysteinaemia.
- Risk factors and associated conditions:
  - Other venous thrombosis,
  - Transient risk factors,
  - Pregnancy,
  - Puerperium,
  - Systemic or brain infections,
  - Systemic inflammatory disease,
  - Haematological disorders,
  - Drugs (oral contraceptives, L-asparaginase therapy, hormone replacement therapy),
  - Malignancies,
  - Bowel disease,
  - Cardiac disease,
  - Mechanical causes and trauma (head injury, surgery, etc),
  - Severe dehydration of any cause.
- Modified Rankin scale at last follow-up.

**Genotyping protocol.**

-DNA isolation kits and stored at −80°C.31

- The power for gene-environment interactions depends on the magnitude of the environmental exposure frequency. Therefore, the power is higher if the exposure frequency is low and is lower if the exposure is high.31

---

We will perform sex stratified analysis, adjusting for age, and conduct several comparisons (eg, between OC users and female non-users, cases with factor V Leiden mutation and cases without the mutation), to highlight the influence of genetic factors between different patient groups. We will also stratify the data by IS status (cases with IS vs cases without IS).

Sample size and power
Power calculations were performed using the genetic power calculator CaTS.32 With the current BEAST repository of 745 CVT cases and a total of ~3000 controls, the study has 80% power to detect a relative risk of 1.6 at a significant p value <10^{-7} with a population allele frequency of 30%. However, the likely genetic liability of this condition17 suggests that this power calculation may be conservative.

DISCUSSION
The BEAST Consortium is the largest DNA repository of highly characterised CVT cases established to-date. The study aims to improve our understanding of the genetics of CVT by first investigating the influence of common and low-frequency genetic variants on CVT risk and, second, by identifying interactions of genetic variants with environmental and comorbidity risk factors. Comprehensive investigation into the genetics of CVT holds the potential to allow at-risk groups to be identified, as well as disease severity and prognosis to be determined.

In the past several years, the genome-wide association (GWA) approach facilitated by technological developments of high-density genome-wide genotyping arrays has been applied for many complex diseases and has been successful in identifying thousands of novel common genetic variants associated with disease risk.33 However, for IS GWA has not been as successful with few genetic variants identified34–39 likely due to the paucity of power in detecting common genetic variants with small effects which require very large cohorts. Another likely reason for the limited positive results is the clinical heterogeneity of IS which is known to be influenced by a heterogeneous collection of disease pathways. Considering that CVT is a rare form of stroke affecting a much younger population and a more clinically homogeneous form of stroke, we hypothesise that it is likely to be influenced by rare genetic variants with potentially larger effects compared with sporadic stroke.

The use of the Illumina Infinium HumanCoreExome BeadChip, which includes a significant number of exonic markers, will increase the probability of identifying functional genetic markers with potential large effects. The exome contains a large amount of rare protein-altering variants (missense, nonsense single-base substitutions, insertion–deletions) that are predicted to have functional roles and/or to be deleterious41 42 which probably account for a considerable amount of the disease-causing mutations.43 Thus, although the initial sample size of our CVT cohort is small due to the low prevalence/incidence of this disease, this highly phenotyped clinical and DNA repository of CVT cases has the potential of identifying novel coding functional variants associated with CVT with potential large effects. Increasing the sample size with more CVT cases and replicating any initial findings is clearly necessary and is being directly addressed by the BEAST Consortium.

Currently, the main limitation of our study is the insufficient power to detect genetic variants with small effects using the genome-wide approach due to the sample size of our study but continuous efforts are being made to enhance enrolment. An important advantage of our study is the thorough phenotyping using stringent inclusion and exclusion criteria and collection of large amount of clinical variables enabling not just genetic analysis but also allowing differences of associated risk factors or outcomes to be evaluated.

Establishing a large DNA repository of CVT cases worldwide will help elucidate its genetics leading to an improvement in our understanding of the pathophysiological mechanisms underlying this disease, identifying groups at risk and potentially facilitating the identification of novel therapeutic targets.

Author affiliations
1Institute of Cardiovascular Research Royal Holloway, University of London (ICR2UL), London, UK
2Department of Gastroenterology and Hepatology, University of Oxford, Oxford, Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, UK
3Department of Restorative Neuroscience, Imperial College London, London, UK
4Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland
5Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
6Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
7Department of Clinical and Experimental Sciences, Neurology Clinic, University of Brescia, Brescia, Italy
8Department of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, Brescia, Italy
9Department of Neurosciences, Hospital de Santa Maria, University of Lisbon, Lisbon, Portugal
10Department of Neurology, University of Utah, Salt Lake City, Utah, USA
11Medical Genetics, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy
12Atherosclerosis and Thrombosis Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
13Department of Neurology, Athens School of Medicine, Eginition Hospital, Athens, Greece
14Stroke Clinic, National Institute of Neurology and Neurosurgery Manuel Velasco Suarez, Mexico City, Mexico
15Department of Pathology and Molecular Medicine, Population Health Research Institute and Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
16Department of Neurology, Bordeaux University Hospital, Bordeaux University, Bordeaux, France
17Neurology Unit, Stroke Unit, Arcispedale Santa Maria Nuova—IRCCS, Reggio Emilia, Italy
18Department of Neurology, Austin Health and Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia
19Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
20Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
Contributors IC was involved in study design, recruitment, contributed to developing the final protocol and drafted the manuscript. TM was involved in study design, recruitment, contributed to developing the final protocol and revising the manuscript. MSK, TP, AH and RD were involved in laboratory analysis and management of samples. SH, EH, TMM, JP, SMZ, MCB, SMP, PB, EP, PC, MC, PC, AT, RS, GF and DC were involved in recruitment and laboratory analysis. MM, EG, MZ, KS, AA, SD, GP, JMF, VT, AP, JJM, IM, JMC and TT are senior investigators who contributed with recruitment and sample collection. PS conceived the idea and is the principal investigator of BEAST who developed the final protocol and drafted the manuscript. All authors contributed intellectually to the protocol and draft versions of the manuscript and approved the final manuscript.

Funding BEAST has received financial support from the Dowager Countess Eleanor Peel Trust and from the Stroke Association.

Competing interests None declared.

Patient consent Obtained.

Ethics approval UK Research Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


